A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)

Inclusion Criteria:

- Men and women at least 18 years of age

- Has prior history of varicella, antibodies to VZV (documented prior to receipt of
blood products), or residence in a country with endemic VZV infection for ≥30 years
or if participant is <30 years old, attended primary or secondary school in a country
with endemic VZV infection.

- Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of
enrollment

- Is highly unlikely to conceive during the time period starting 2 weeks prior to
enrollment through 6 months from last vaccination dose

- Female participants of childbearing potential must have a negative serum or urine
pregnancy test.

Exclusion Criteria:

- History of hypersensitivity reaction to any vaccine component

- Prior history of herpes zoster within 1 year of enrollment

- Prior receipt of any varicella or zoster vaccine

- More than 2 relapses of the underlying cancer (participants with Hodgkin's lymphoma
may have had more than 2 relapses)

- Expectation of tandem transplant procedure

- Is expected to receive >6 months (>180 days) of prophylactic antiviral therapy
post-HCT.

- Is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks
prior to enrollment through 6 months from last vaccination dose.

- Has received a live virus vaccine or is scheduled to receive a live virus vaccine in
the period from 4 weeks prior to Dose 1 through 28 days Postdose 4.

- Has received an inactivated vaccine or is scheduled to receive an inactivated vaccine
in the period between 7 days prior to and 28 days following Doses 1 through 4.